PMID- 23064051
OWN - NLM
STAT- MEDLINE
DCOM- 20130403
LR  - 20220331
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 94
IP  - 1
DP  - 2013 Feb
TI  - Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell 
      lung cancer patients.
PG  - 301-8
LID - S0014-4800(12)00153-0 [pii]
LID - 10.1016/j.yexmp.2012.10.006 [doi]
AB  - Metallothioneins (MT) are intracellular, low molecular weight proteins (6-7 kDa) 
      involved in binding of metal ions, scavenging of free radicals, cell 
      proliferation and apoptosis and resistance to certain chemotherapeutics. Four 
      basic families of MT proteins are distinguished: MT-I, MT-II, MT-III, MT-IV, 
      within each of them different isoforms occur. The study aimed at examining the 
      expression level of nine MT isoforms: MT-1A, -1B, -1E, -1F, -1G, -1H, -1X, MT-2A 
      and MT-IV by using real-time PCR and MT-I/II expression by immunohistochemical 
      (IHC) technique in 69 cases of non-small cell lung cancer (NSCLC) and 12 
      non-malignant lung tissues (NMLT) and to correlate them with patients 
      clinicopathological data and Ki-67 antigen expression. Out of all the analyzed 
      cases, 62 (89.9%) demonstrated an increased MT-I/II expression. MT-1B, 1F, -1G, 
      -1H and MT-1X were significantly up-regulated, whereas MT-1E was significantly 
      down-regulated in NSCLC as compared to NMLT. Only in two cases MT-IV mRNA 
      expression was noted. Significant positive correlations were observed between 
      each particular MT isoform expressions. Higher MT-1F and MT-1A mRNA expression 
      was associated with larger primary tumor size (P=0.0362 and P<0.0001, 
      respectively). Moreover, up-regulated MT-1F mRNA expression was associated with 
      higher grade of malignancy of NSCLC (P=0.0085). Higher MT-1B mRNA expression was 
      associated with squamocellular and adenocarcinoma subtype of NSCLC (P=0.0358). 
      Univariate analysis showed, that up-regulated MT-1F and MT-2A mRNA predicted poor 
      patients' survival (P=0.0206 and P=0.0097, respectively). The levels of MT-1F and 
      MT-2A mRNA could be considered as new markers of poor prognosis of NSCLC 
      patients.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Werynska, Bozena
AU  - Werynska B
AD  - Department of Pulmonology and Pulmonary Tumours, Medical University in Wroclaw, 
      Poland.
FAU - Pula, Bartosz
AU  - Pula B
FAU - Muszczynska-Bernhard, Beata
AU  - Muszczynska-Bernhard B
FAU - Gomulkiewicz, Agnieszka
AU  - Gomulkiewicz A
FAU - Piotrowska, Aleksandra
AU  - Piotrowska A
FAU - Prus, Robert
AU  - Prus R
FAU - Podhorska-Okolow, Marzena
AU  - Podhorska-Okolow M
FAU - Jankowska, Renata
AU  - Jankowska R
FAU - Dziegiel, Piotr
AU  - Dziegiel P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121009
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (MT1F protein, human)
RN  - 0 (MT2A protein, human)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Messenger)
RN  - 9038-94-2 (Metallothionein)
SB  - IM
MH  - Biomarkers, Tumor/biosynthesis/genetics
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/pathology
MH  - Down-Regulation
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen/biosynthesis
MH  - Lung Neoplasms/*metabolism/pathology
MH  - Male
MH  - Metallothionein/*biosynthesis/genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Protein Isoforms/biosynthesis
MH  - RNA, Messenger/biosynthesis
MH  - Up-Regulation
EDAT- 2012/10/16 06:00
MHDA- 2013/04/04 06:00
CRDT- 2012/10/16 06:00
PHST- 2012/05/13 00:00 [received]
PHST- 2012/10/02 00:00 [revised]
PHST- 2012/10/03 00:00 [accepted]
PHST- 2012/10/16 06:00 [entrez]
PHST- 2012/10/16 06:00 [pubmed]
PHST- 2013/04/04 06:00 [medline]
AID - S0014-4800(12)00153-0 [pii]
AID - 10.1016/j.yexmp.2012.10.006 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2013 Feb;94(1):301-8. doi: 10.1016/j.yexmp.2012.10.006. Epub 2012 
      Oct 9.